2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-115356
    Eoxin E4 1000852-57-2 98%
    Eoxin E4 (14,15-LTE4) is the metabolite of 14,15-LTC4 and 14,15-LTD4. Eoxin E4 increases vascular permeability of human endothelial cell monolayers with about 10-fold less potency than LTC4, but approximately 100-fold greater potency than histamine.
    Eoxin E4
  • HY-115382
    Guanoctine hydrochloride 1070-95-7 98%
    Guanoctine hydrochloride exhibits antihypertensive properties.
    Guanoctine hydrochloride
  • HY-115390
    14,15-Dehydro Leukotriene B4 114616-11-4 98%
    14,15-Dehydro Leukotriene B4 (Compound 4) is a LTB4 receptor antagonist. 14,15-Dehydro Leukotriene B4 also has a higher binding affinity for BLT1 with a Ki value of 27 nM and BLT2 with a Ki value of 473 nM. 14,15-Dehydro Leukotriene B4 inhibits LTB4-induced release of lysozymes from rat polymorphonuclear leukoctyes with an IC50 value of 1 µM.
    14,15-Dehydro Leukotriene B4
  • HY-115420
    1-β-D-Glucosylsphingadienine (d18:2 (4E8E)) 114200-59-8 98%
    1-β-D-Glucosylsphingadienine (d18:2 (4E8E)) is a glucosylsphingosine, which are deacetylated lysolipid derivatives of glucosylcerebrosides.
    1-β-D-Glucosylsphingadienine (d18:2 (4E8E))
  • HY-115477
    Brilaroxazine hydrochloride 1708960-04-6 98%
    Brilaroxazine (RP5063) hydrochloride is a modulator of serotonin receptors, exhibiting potential therapeutic activity in the treatment of pulmonary arterial hypertension (PAH). Brilaroxazine hydrochloride has been shown to limit functional and structural changes associated with PAH, leading to significant improvements in pulmonary hemodynamics and right ventricular hypertrophy. Brilaroxazine hydrochloride also enhances oxygen saturation levels and alleviates elevated pulmonary arterial pressures when used as an adjunct to standard PAH therapies.
    Brilaroxazine hydrochloride
  • HY-115494
    Neladenoson dalanate hydrochloride 1239235-25-6 98%
    Neladenoson dalanate (Neladenoson bialanate; BAY-1067197) hydrochloride is a orally active agonist precursor of partial Adenosine A1 Receptor. Neladenoson dalanate hydrochloride has a good pharmacokinetic and safety profile, can be used for the chronic heart diseases.
    Neladenoson dalanate hydrochloride
  • HY-115780
    E17110 1090785-30-0 98%
    E17110 is a liver X receptor β (LXRβ) agonist with an EC50 of 0.72 μM. E17110 can increase the expression of ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) in RAW264.7 macrophages. E17110 also reduce cellular lipid accumulation and promoted cholesterol efflux. E17110 can be used for the research of cardiovascular disease, such as atherosclerosis.
    E17110
  • HY-115911
    GPVI antagonist 2 880399-00-8 99.24%
    GPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent.
    GPVI antagonist 2
  • HY-115912
    GPVI antagonist 3 901654-94-2 98%
    GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent.
    GPVI antagonist 3
  • HY-116042
    FSCPX 156547-56-7 99.72%
    FSCPX is a potent and selective irreversible antagonist of A1 adenosine receptor (A1AR), with low nanomolar potency for binding to the A1AR. FSCPX could modify the effect of NBTI, a nucleoside transport inhibitor, by reducing the interstitial adenosine level in the guinea pig atrium.
    FSCPX
  • HY-116050
    17(S)-HETE 183509-25-3 98%
    17S-HETE is arachidonic acid metabolite through cytochrome P-450 pathways. 17S-HETE serves as allosteric activator of the cytochrome P450 1B1 and inhibitor of ATPase, induces cardic hypertrophy.
    17(S)-HETE
  • HY-116051
    16,16-Dimethylprostaglandin F2α 39746-23-1 98%
    16,16-Dimethylprostaglandin F2α (16,16-Dimethyl-PGF2α) is a potent analog of PGF2α (HY-12956), which exhibits similar binding potency as PGF2α does. 16,16-Dimethylprostaglandin F2α serves as a bronchoconstrictor.
    16,16-Dimethylprostaglandin F2α
  • HY-116119
    BDF 9148 120838-62-2 98%
    BDF 9148 is a sodium-channel activator with antiarrhythmic properties that produces a significant CAMP-independent positive inotropic effect in left ventricular myocardium from failing hearts. BDF 9148 is promising for research of myocardial failure.
    BDF 9148
  • HY-116158
    Oosponol 146-04-3 98%
    Oosponol is a dopamine beta-hydroxylase inhibitor exhibiting hypotensive effects.Oospongol has strong antifungal activity against many antagonistic fungi.
    Oosponol
  • HY-116161
    Bimatoprost isopropyl ester 130273-87-9 98%
    15(R)-17-phenyl trinor Prostaglandin F2α isopropyl ester (15(R)-17-phenyl trinor PGF2α isopropyl ester) is the latanoprost-related isomer containing both a double bond at 13,14 and an inverted (β) hydroxyl group at C-15. Similar to 15(S)-latanoprost, 15(R)-17-phenyl trinor PGF2α isopropyl ester is a potential impurity in most commercial preparations of the latanoprost bulk drug product. The IC50 values for the free acid forms of 15(S)-17-phenyl trinor PGF2α and 15(R)-17-phenyl trinor PGF2α were determined to be 0.71 nM and 30 nM, respectively, in a FP receptor binding assay using the cat iris sphincter muscle.1 A 3 μg dose of 15(R)-17-phenyl trinor PGF2α caused a 1.9 mmHg reduction of IOP in normotensive cynomolgus monkeys.
    Bimatoprost isopropyl ester
  • HY-116244
    Ro 48-8587 211120-62-6 98%
    Ro 48-8587 is a selective AMPA receptor antagonist with an IC50 of 8 nM. Ro 48-8587 functionally inhibits AMPA receptor activity, blocks AMPA-induced depolarization of rat cortical wedges. Ro 48-8587 can be used for the research of ischaemia and seizures.
    Ro 48-8587
  • HY-116294
    Methoctramine 104807-40-1 98%
    Methoctramine is a potent and cardioselectivity antagonist of M2 muscarinic receptor. Methoctramine can inhibit Muscarine (HY-121404)-induced bradycardia in vivo. Methoctramine can be used in the study of cardiovascular diseases.
    Methoctramine
  • HY-116295
    MRS2690 7077-89-6 98%
    MRS2690 is a selective P2Y14 receptor agonist. MRS2690 inhibits adenylyl cyclase activity, thereby reducing intracellular cAMP levels and mediating concentration-dependent vasoconstriction of porcine coronary arteries. MRS2690 induces intracellular calcium mobilization, activates P38 and stimulates [35S]GTPγS binding to RBL-2H3 cell membranes. MRS2690 enhances antigen (NP-BSA)-, C3a-induced β-hexosaminidase (β-Hex) release. MRS2690can be used for ischemic heart disease.
    MRS2690
  • HY-116312
    8-pCPT-2′-O-Me-cAMP 510774-50-2 98%
    8-pCPT-2′-O-Me-cAMP (8-CPT-2'-O-Me-cAMP), an analog of cAMP, is an activator of exchange proteins activated by cAMP (Epac). 8-pCPT-2′-O-Me-cAMP activates Epac1 (EC50 = 2.2 μM), but not PKA (EC50 >10 μM). 8-pCPT-2′-O-Me-cAMP stimulates Epac-mediated Ca2+ release in pancreatic β-cells in vitro. 8-pCPT-2′-O-Me-cAMP is a Rap1 activator. 8-pCPT-2′-O-Me-cAMP enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration.
    8-pCPT-2′-O-Me-cAMP
  • HY-116363
    (21R)-Argatroban 121785-71-5 98%
    (21R)-Argatroban is a diastereoisomer of Argatroban (HY-B0375). (21R)-Argatroban is also an inhibitor of thrombin with anticoagulant activity. (21R)-Argatroban can be used for research related to anticoagulation.
    (21R)-Argatroban
Cat. No. Product Name / Synonyms Application Reactivity